Back to discover
Drug

Alanine

In clinical development
Emerging researchEarly-to-mid developmentRising momentum
Also known as (2S)-2-aminopropanoic acid, (S)-2-aminopropanoic acid, (S)-alanine, 2-aminopropionic acid+43 more

(2S)-2-aminopropanoic acid, (S)-2-aminopropanoic acid, (S)-alanine, 2-aminopropionic acid, Alpha-aminopropionic acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Freamine III 10, Hepatamine 8, Hepatasol, L-2-Aminopropionic acid, L-Alanin, L-Alanine, L-alpha-Alanine, Plenamine, PremaSol, ProSol, ProcalAmine 3, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, Alanina, Alaninum, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25.

RxNorm426ChEMBLCHEMBL279597UNIIOF5P57N2ZX
3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes

Clinical trial2026-01-16Completed · ClinicalTrials.gov

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals

Clinical trial2024-05-01Primary completion · ClinicalTrials.gov

The metabolic effects of intermittent versus continuous feeding in critically ill patients.

Research2023-11-09Scientific reports

Efficacy of Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

Clinical trial2020-06-11Results posted · ClinicalTrials.gov

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

Research2020-02-24The Journal of biological chemistry

A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis

Clinical trial2006-06-01Completed · ClinicalTrials.gov

Study of Gluconeogenesis in Very Low Birth Weight Infants Receiving Total Parenteral Nutrition

Clinical trial2005-06-24Status unknown · ClinicalTrials.gov

Long-term synaptic depression in the striatum: physiological and pharmacological characterization.

Research1992-11-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Alanine
Aliases & brands
(2S)-2-aminopropanoic acid(S)-2-aminopropanoic acid(S)-alanine2-aminopropionic acidAlpha-aminopropionic acidAminosyn 10%, Sulfite-FreeAminosyn 3.5 % M, Sulfite FreeAminosyn 8.5 % with Electrolytes, Sulfite-FreeAminosyn 8.5%, Sulfite-FreeAminosyn II 10 %Aminosyn II 15%Aminosyn II 8.5 % with Electrolytes, Sulfite-FreeAminosyn II 8.5 %, Sulfite-FreeAminosyn-HBC 7 %, Sulfite-FreeAminosyn-PF 10 %, Sulfite-FreeAminosyn-PF 7%Clinisol 15Freamine III 10Hepatamine 8HepatasolL-2-Aminopropionic acidL-AlaninL-AlanineL-alpha-AlaninePlenaminePremaSolProSolProcalAmine 3Travasol 10Travasol 10%TrophamineTrophamine 10 %Trophamine 6 %AlaninaAlaninumClinimix 4.25/10Clinimix 4.25/25Clinimix 4.25/5Clinimix 5/15Clinimix 5/20Clinimix 5/25Clinimix E 2.75/5Clinimix E 4.25/10Clinimix E 4.25/5Clinimix E 5/15Clinimix E 5/20Clinimix E 5/25
RxNorm CUI
426
ChEMBL ID
CHEMBL279597
UNII
OF5P57N2ZX

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2026
4
Late-stage (III+)
3
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 5
Phase 11Phase N / A4

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19922023
Major research themes2
Amino Acids1Critical Illness1
Journals, researchers & institutions
Top journals
  • Scientific reports1
  • The Journal of biological chemistry1
  • The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers
  • Atherton PJ1
  • Bear DE1
  • Bernardi G1
  • Calabresi P1
  • Conte MR1
  • Feng JY1
  • Francis T1
  • Gallagher IJ1
Leading institutions
free-text, unnormalised
  • Centre for Biomolecular Spectroscopy1
  • Centre for Human and Applied Physiological Science1
  • Clinica Neurologica1
  • Department of Medicine and Centre for Human Health and Performance1
  • Department of Nutrition and Dietetics St Thomas' NHS Foundation Trust1
  • Guy's & St Thomas' Foundation Trust1

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Amino Acids

Studied across the same disease area as Alanine in the shared literature.

1 shared disease1 shared paper
Dopamine

Frequently co-studied with Alanine in the research literature.

1 shared paper
Remdesivir

Frequently co-studied with Alanine in the research literature.

1 shared paper
Scopolamine

Frequently co-studied with Alanine in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials